Ascendis Pharma A/S (ASND)

Market Cap	9.72B
Revenue (ttm)	398.51M
Net Income (ttm)	-369.30M
Shares Out	60.37M
EPS (ttm)	-6.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,058
Open	162.31
Previous Close	162.84
Day's Range	160.01 - 164.81
52-Week Range	111.09 - 183.00
Beta	0.40
Analysts	Strong Buy
Price Target	213.88 (+32.85%)
Earnings Date	May 1, 2025

About ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on adv...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 1,017
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND
• Website: https://ascendispharma.com

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 16 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is $213.88, which is an increase of 32.85% from the latest price.

Price Target

$213.88

(32.85% upside)

Analyst Consensus: Strong Buy